Chapter 9 : Viral Hemorrhagic Fevers: a Comparative Appraisal

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Viral Hemorrhagic Fevers: a Comparative Appraisal, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap09-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap09-2.gif


This chapter provides a general survey of viral hemorrhagic fever (VHF), comparing individual diseases to each other and to other types of human illness. The HF viruses belong to four different families, the , , , and . The various types of VHF have presumably occurred for millennia, whenever humans have come into contact with reservoir animals or been bitten by infected arthropods. The transmission of a virus from animals to humans can occur through direct physical contact, exposure to virus containing excretions, or the bite of an infected mosquito or tick. Lassa fever, among other things, is characterized by uncontrolled viral replication, in which the circulating viral titer correlates with the likelihood of death. The circulation of more than one serotype in the same geographic region sets the stage for the occurrence of secondary infections, in which nonneutralizing antibodies can enhance virus uptake into cells, causing intense inflammation and increased vascular permeability. At present, the best-understood form of VHF is the fulminant illness caused by Ebola Zaire virus, which displays all the classic features of the HF syndrome. The signs and symptoms of VHF resemble those of a wide range of infectious diseases, so a specific diagnosis can be made only by means of specialized laboratory tests that directly identify the pathogen. Considerable progress has been made in developing experimental vaccines for a number of types of VHF, based on a variety of platforms.

Citation: Bray M, Johnson K. 2009. Viral Hemorrhagic Fevers: a Comparative Appraisal, p 133-141. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch9
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Basler, C. F. 2005. Interferon antagonists encoded by emerging RNA viruses, p. 197–220. In P. Palese (ed.), Modulation of Host Gene Expression and Innate Immunity by Viruses. Springer, Dordrecht, The Netherlands.
2. Basler, C. F.,, A. Mikulasova,, L. Martinez-Sobrido,, J. Paragas,, E. Muhlberger,, M. Bray,, H. D. Klenk,, P. Palese, and, A. Garcia-Sastre. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77: 79457956.
3. Bowen, M.,, C. J. Peters, and, S. T. Nichol. 1997. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation among arenaviruses and their rodent hosts. Mol. Phylogenet. Evol. 8: 301316.
4. Bradfute, S. B.,, K. L. Warfield, and, S. Bavari. 2008. Functional CD8+ T cell responses in lethal Ebola virus infection. J. Immunol. 180: 40584066.
5. Bray, M. 2005. Pathogenesis of viral hemorrhagic fever. Curr. Opin. Immunol. 17: 399403.
6. Bray, M.,, and T. W. Geisbert. 2005. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell Biol. 37: 15601566.
7. Burt, F. J.,, R. Swanepoel,, W. J. Shieh,, J. F. Smith,, P. A. Leman,, P. W. Greer,, L. M. Coffield,, P. E. Rollin,, T. G. Ksiazek,, C. J. Peters, and, S. R. Zaki. 1997. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch. Pathol. Lab. Med. 121: 839846.
8. Casals, J.,, H. Hoogstraal,, K. M. Johnson,, A. Shelokov,, N. H. Wiebenga, and, T. H. Work. 1966. A current appraisal of hemorrhagic fevers in the U.S.S.R. Am. J. Trop. Med. Hyg. 15: 751764.
9. Enria, D. A.,, A. M. Briggiler, and, Z. Sanchez. 2008. Treatment of Argentine hemorrhagic fever. Antiviral. Res. 78: 132139.
10. Ergonul, O. 2006. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 6: 203214.
11. Fisher-Hoch, S. P. 2005. Lessons from nosocomial viral haemorrhagic fever outbreaks. Br. Med. Bull. 73–74: 123137.
12. Gajdusek, D. C. 1962. Virus hemorrhagic fevers. Special reference to hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever). J. Pediatr. 60: 841857.
13. Geisbert, T. W.,, K. M. Daddario-DiCaprio,, K. J. Williams,, J. B. Geisbert,, A. Leung,, F. Feldmann,, L. E. Hensley,, H. Feldmann, and, S. M. Jones. 2008. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in non-human primates. J. Virol. 82: 56645668.
14. Geisbert, T. W.,, L. E. Hensley,, T. R. Gibb,, K. E. Steele,, N. K. Jaax, and, P. B. Jahrling. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Investig. 80: 171186.
15. Geisbert, T. W.,, L. E. Hensley,, P. B. Jahrling,, T. Larsen,, J. B. Geisbert,, J. Paragas,, H. A. Young,, T. M. Fredeking,, W. E. Rote, and, G. P. Vlasuk. 2003. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362: 19531958.
16. Geisbert, T. W.,, H. A. Young,, P. B. Jahrling,, K. J. Davis,, E. Kagan, and, L. E. Hensley. 2003. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188: 16181629.
17. Geisbert, T. W.,, H. A. Young,, P. B. Jahrling,, K. J. Davis,, T. Larsen,, E. Kagan, and, L. E. Hensley. 2003. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol. 163: 23712382.
18. Gubler, D. J. 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found. Symp. 277: 316; discussion, 16–22, 71–73, 251–253.
19. Hensley, L. E.,, E. L. Stevens,, S. B. Yan,, J. B. Geisbert,, W. L. Macias,, T. Larsen,, K. M. Daddario-DiCaprio,, G. H. Cassell,, P. B. Jahrling, and, T. W. Geisbert. 2007. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196 (Suppl. 2): S390S399.
20. Huggins, J. W. 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11 (Suppl. 4): S750S761.
21. Jeffs, B. 2006. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop. Dr. 36: 14.
22. Jones, S. M.,, H. Feldmann,, U. Stroher,, J. B. Geisbert,, L. Fernando,, A. Grolla,, H. D. Klenk,, N. J. Sullivan,, V. E. Volchkov,, E. A. Fritz,, K. M. Daddario,, L. E. Hensley,, P. B. Jahrling, and, T. W. Geisbert. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11: 786790.
23. Jonsson, C. B.,, J. Hooper, and, G. Mertz. 2008. Treatment of hantavirus pulmonary syndrome. Antivir. Res. 78: 162169.
24. Khan, S. H.,, A. Goba,, M. Chu,, C. Roth,, T. Healing,, A. Marx,, J. Fair,, M. C. Guttieri,, P. Ferro,, T. Imes,, C. Monagin,, R. F. Garry, and, D. G. Bausch. 2008. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antivir. Res. 78: 103115.
25. Ksiazek, T. G.,, P. E. Rollin,, A. J. Williams,, D. S. Bressler,, M. L. Martin,, R. Swanepoel,, F. J. Burt,, P. A. Leman,, A. S. Khan,, A. K. Rowe,, R. Mukunu,, A. Sanchez, and, C. J. Peters. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1): S177S187.
26. Kurane, I. 2007. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp. Immunol. Microbiol. Infect. Dis. 30: 329340.
27. Mahanty, S.,, and M. Bray. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4: 487498.
28. Mahanty, S.,, K. Hutchinson,, S. Agarwal,, M. McRae,, P. E. Rollin, and, B. Pulendran. 2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170: 27972801.
29. McCormick, J. B.,, I. J. King,, P. A. Webb,, C. L. Scribner,, R. B. Craven,, K. M. Johnson,, L. H. Elliott, and, R. Belmont-Williams. 1986. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314: 2026.
30. Monath, T. P. 2008. Treatment of yellow fever. Antivir. Res. 78: 116124.
31. Myhrman, G. 1951. Nephropathia epidemica: a new infectious disease in northern Scandinavia. Acta Med. Scand. 140: 5256.
32. Parrino, J.,, R. S. Hotchkiss, and, M. Bray. 2007. Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg. Infect. Dis. 13: 191198.
33. Pigott, D. C. 2005. Hemorrhagic fever viruses. Crit. Care Clin. 21: 765783.
34. Spurgers, K. B.,, C. M. Sharkey,, K. L. Warfield, and, S. Bavari. 2008. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antivir. Res. 78: 2636.
35. ter Meulen, J.,, M. Sakho,, K. Koulemou,, N. Magassouba,, A. Bah,, W. Preiser,, S. Daffis,, C. Klewitz,, H. G. Bae,, M. Niedrig,, H. Zeller,, M. Heinzel-Gutenbrunner,, L. Koivogui, and, A. Kaufmann. 2004. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J. Infect. Dis. 190: 18211827.
36. Whitehead, S. S.,, J. E. Blaney,, A. P. Durbin, and, B. R. Murphy. 2007. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5: 518528.
37. Zaki, S. R.,, P. W. Greer,, L. M. Coffield,, C. S. Goldsmith,, K. B. Nolte,, K. Foucar,, R. M. Feddersen,, R. E. Zumwalt,, G. L. Miller,, A. S. Khan,, P. E. Rollin,, T. G. Ksiazek,, S. T. Nichol,, B. W. J. Mahy, and, C. J. Peters. 1995. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am. J. Pathol. 146: 552579.


Generic image for table

Some epidemiological features of the principal types of VHF

Citation: Bray M, Johnson K. 2009. Viral Hemorrhagic Fevers: a Comparative Appraisal, p 133-141. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch9

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error